PriceTargets.com logo

Oruka Therapeutics - ORKA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $54.50
  • Forecasted Upside: 69.20%
  • Number of Analysts: 9
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$32.21 As of 02/13/2026 05:00 PM ET
▼ -0.43 (-1.32%)

This chart shows the closing price for ORKA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oruka Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ORKA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ORKA

Analyst Price Target is $54.50
▲ +69.20% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Oruka Therapeutics in the last 3 months. The average price target is $54.50, with a high forecast of $75.00 and a low forecast of $40.00. The average price target represents a 69.20% upside from the last price of $32.21.

This chart shows the closing price for ORKA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 9 polled investment analysts is to moderate buy stock in Oruka Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/26/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/24/2024
  • 2 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/22/2025
  • 2 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/23/2025
  • 2 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/21/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/19/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/18/2026
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
2/17/2026

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/22/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/13/2026WedbushBoost TargetOutperform ➝ Outperform$42.00 ➝ $45.00
1/12/2026BTIG ResearchBoost TargetBuy ➝ Buy$63.00 ➝ $73.00
1/7/2026UBS GroupInitiated CoverageBuy$50.00
1/7/2026UBS GroupInitiated CoverageBuy$50.00
12/18/2025Piper SandlerInitiated CoverageOverweight$75.00
11/13/2025BTIG ResearchBoost TargetBuy ➝ Buy$56.00 ➝ $63.00
11/13/2025Jefferies Financial GroupInitiated CoverageBuy$45.00
10/27/2025HC WainwrightLower TargetBuy ➝ Buy$45.00 ➝ $40.00
10/27/2025GuggenheimInitiated CoverageBuy$60.00
10/13/2025BarclaysInitiated CoverageOverweight$48.00
10/13/2025BarclaysInitiated CoverageOverweight$48.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/29/2025BTIG ResearchReiterated RatingBuy ➝ Buy$56.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/17/2025BTIG ResearchBoost TargetBuy ➝ Buy$44.00 ➝ $56.00
8/18/2025HC WainwrightReiterated RatingBuy ➝ Buy$45.00
8/12/2025WedbushReiterated RatingOutperform$40.00
7/23/2025HC WainwrightReiterated RatingBuy ➝ Buy$45.00
7/21/2025WedbushReiterated RatingOutperform$40.00
5/22/2025BTIG ResearchInitiated CoverageBuy
5/22/2025BTIG ResearchUpgradeStrong-Buy$44.00
5/15/2025WedbushReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.00
3/7/2025WedbushReiterated RatingOutperform$40.00
2/7/2025HC WainwrightReiterated RatingBuy ➝ Buy$45.00 ➝ $45.00
2/4/2025Wolfe ResearchInitiated CoverageOutperform$20.00
2/3/2025Wolfe ResearchUpgradeStrong-Buy
12/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$45.00 ➝ $45.00
11/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$45.00 ➝ $45.00
11/19/2024WedbushReiterated RatingOutperform$40.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$45.00 ➝ $45.00
10/11/2024Stifel NicolausInitiated CoverageBuy$49.00
10/7/2024HC WainwrightInitiated CoverageBuy$45.00
9/17/2024Leerink PartnersUpgradeStrong-Buy
9/17/2024Leerink PartnersInitiated CoverageOutperform$44.00
9/16/2024Lifesci CapitalInitiated CoverageOutperform$41.00
9/16/2024TD CowenInitiated CoverageBuy
9/13/2024Jefferies Financial GroupInitiated CoverageBuy$40.00
9/4/2024WedbushInitiated CoverageOutperform$40.00
9/3/2024WedbushUpgradeStrong-Buy
(Data available from 2/17/2021 forward)

News Sentiment Rating

0.97 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/22/2025
  • 6 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2025
  • 10 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2025
  • 5 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2025
  • 6 very positive mentions
  • 20 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 8 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026

Current Sentiment

  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Oruka Therapeutics logo
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Read More

Today's Range

Now: $32.21
Low: $31.95
High: $33.96

50 Day Range

MA: $31.61
Low: $26.40
High: $35.53

52 Week Range

Now: $32.21
Low: $5.49
High: $36.51

Volume

187,058 shs

Average Volume

424,386 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Oruka Therapeutics?

The following equities research analysts have issued reports on Oruka Therapeutics in the last twelve months: Barclays PLC, BTIG Research, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Piper Sandler, UBS Group AG, Wall Street Zen, Wedbush, and Weiss Ratings.
View the latest analyst ratings for ORKA.

What is the current price target for Oruka Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Oruka Therapeutics in the last year. Their average twelve-month price target is $54.50, suggesting a possible upside of 69.2%. Piper Sandler has the highest price target set, predicting ORKA will reach $75.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $40.00 for Oruka Therapeutics in the next year.
View the latest price targets for ORKA.

What is the current consensus analyst rating for Oruka Therapeutics?

Oruka Therapeutics currently has 1 sell rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ORKA.

What other companies compete with Oruka Therapeutics?

Other companies that are similar to Oruka Therapeutics include Kymera Therapeutics, PTC Therapeutics, Mirum Pharmaceuticals, Cogent Biosciences and Immunovant. Learn More about companies similar to Oruka Therapeutics.

How do I contact Oruka Therapeutics' investor relations team?

Oruka Therapeutics' physical mailing address is 10170 CHURCH RANCH WAY SUITE 100, WESTMINSTER CO, 80021. The company's listed phone number is 720-940-2100 and its investor relations email address is [email protected]. The official website for Oruka Therapeutics is www.arcabio.com. Learn More about contacing Oruka Therapeutics investor relations.